全文获取类型
收费全文 | 1603472篇 |
免费 | 131309篇 |
国内免费 | 2581篇 |
专业分类
耳鼻咽喉 | 21664篇 |
儿科学 | 52984篇 |
妇产科学 | 46284篇 |
基础医学 | 227883篇 |
口腔科学 | 47241篇 |
临床医学 | 141160篇 |
内科学 | 315126篇 |
皮肤病学 | 34166篇 |
神经病学 | 130184篇 |
特种医学 | 64746篇 |
外国民族医学 | 474篇 |
外科学 | 244003篇 |
综合类 | 39786篇 |
现状与发展 | 3篇 |
一般理论 | 554篇 |
预防医学 | 122980篇 |
眼科学 | 36486篇 |
药学 | 121350篇 |
3篇 | |
中国医学 | 2975篇 |
肿瘤学 | 87310篇 |
出版年
2018年 | 14765篇 |
2016年 | 12905篇 |
2015年 | 15047篇 |
2014年 | 20669篇 |
2013年 | 31372篇 |
2012年 | 42552篇 |
2011年 | 44756篇 |
2010年 | 26374篇 |
2009年 | 25356篇 |
2008年 | 43004篇 |
2007年 | 45245篇 |
2006年 | 46052篇 |
2005年 | 44680篇 |
2004年 | 44090篇 |
2003年 | 42188篇 |
2002年 | 41294篇 |
2001年 | 75697篇 |
2000年 | 78339篇 |
1999年 | 66416篇 |
1998年 | 17763篇 |
1997年 | 16400篇 |
1996年 | 16362篇 |
1995年 | 16057篇 |
1994年 | 15115篇 |
1993年 | 14253篇 |
1992年 | 55461篇 |
1991年 | 53808篇 |
1990年 | 52603篇 |
1989年 | 50862篇 |
1988年 | 47259篇 |
1987年 | 46591篇 |
1986年 | 44308篇 |
1985年 | 42855篇 |
1984年 | 32054篇 |
1983年 | 27578篇 |
1982年 | 16166篇 |
1981年 | 14452篇 |
1980年 | 13580篇 |
1979年 | 30483篇 |
1978年 | 21074篇 |
1977年 | 17777篇 |
1976年 | 16706篇 |
1975年 | 17584篇 |
1974年 | 21490篇 |
1973年 | 20678篇 |
1972年 | 18862篇 |
1971年 | 17779篇 |
1970年 | 16293篇 |
1969年 | 15271篇 |
1968年 | 13954篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
41.
42.
43.
44.
45.
R. E. J. Ryder 《Diabetic medicine》2015,32(3):305-313
On 8 April 2014, a US jury ordered Takeda and Eli Lilly to pay $9 bn in punitive damages after finding that they had concealed the cancer risks associated with pioglitazone. By contrast, on 28 August 2014, the long‐awaited outcome of the 10‐year Kaiser Permanente Northern California study was announced. That study was specifically designed to investigate whether patients exposed to pioglitazone were at an increased risk of bladder cancer and found no association; thus, at last, the controversial issue has been resolved. A review, in retrospect, of the story of the proposed link between pioglitazone and bladder cancer reveals flaws at every stage. In 2012, a BMJ editorial, in keeping with some other contemporary reports, stated ‘it can confidently be assumed that pioglitazone increases the risk of bladder cancer’. Examination of the information which led to such a statement shows that: 1) the pre‐clinical findings of bladder cancer in male rats is not indicative of human risk; 2) there is no association between bladder cancer and pioglitazone in randomized controlled trials, once cases that could not plausibly be related to treatment are removed; and 3) the observational studies that have suggested a link have over‐extrapolated from the data: pioglitazone‐treated patients had more risk factors for bladder cancer than those not treated with pioglitazone. Meanwhile careful study of randomized controlled trials shows evidence of cardiovascular benefit from pioglitazone in Type 2 diabetes, a condition which results, more than anything, in premature cardiovascular death and morbidity. 相似文献
46.
M. Alexandra Friedman Charlotte M. Niznik Janelle R. Bolden Lynn M. Yee 《Journal of community health》2016,41(2):354-358
While peer support has been investigated in multiple clinical contexts, its application to the postpartum setting is unknown. The aim was to assess acceptability of a postpartum peer support program for women with diabetes. Observational survey-based needs assessment of forty low-income women with diabetes, receiving care at a major medical institution. Mean age and gravidity were 30.7 years and 3.15 ± 1.67 respectively. 45 % expressed interest in a “buddy.” There was no significant difference between groups desiring and not desiring this program. A majority of respondents desired telephone, text messaging, and in-person contacts (79.2, 72.1, 83.8 %), with 72.5 % of patients desiring diabetes-related activities during clinic waiting time. Many women desire a postpartum diabetes reciprocal peer program for support outside of clinician visits. Patients are receptive to educational services during their wait and outside of clinic time, a potentially valuable opportunity to share important health information. 相似文献
47.
48.
49.
Clint R. Bellenger John B. Arnold Jonathan D. Buckley Dominic Thewlis Joel T. Fuller 《Journal of Science and Medicine in Sport》2019,22(3):294-299
Objectives
To investigate whether functional overreaching affects locomotor system behaviour when running at fixed relative intensities and if any effects were associated with changes in running performance.Design
Prospective intervention study.Methods
Ten trained male runners completed three training blocks in a fixed order. Training consisted of one week of light training (baseline), two weeks of heavy training designed to induce functional overreaching, and ten days of light taper training designed to allow athletes to recover from, and adapt to, the heavy training. Locomotor behaviour, 5-km time trial performance, and subjective reports of training status (Daily Analysis of Life Demands for Athletes (DALDA) questionnaire) were assessed at the completion of each training block. Locomotor behaviour was assessed using detrended fluctuation analysis of stride intervals during running at speeds corresponding to 65% and 85% of maximum heart rate (HRmax) at baseline.Results
Time trial performance (effect size ±95% confidence interval (ES): 0.16 ± 0.06; p < 0.001), locomotor behaviour at 65% HRmax (ES: ?1.12 ± 0.95; p = 0.026), and DALDA (ES: 2.55 ± 0.80; p < 0.001) were all detrimentally affected by the heavy training. Time trial performance improved relative to baseline after the taper (ES: ?0.16 ± 0.10; p = 0.003) but locomotor behaviour at 65% HRmax (ES: ?1.18 ± 1.17; p = 0.048) and DALDA (ES: 0.92 ± 0.90; p = 0.045) remained impaired.Conclusions
Locomotor behaviour during running at 65% HRmax was impaired by functional overreaching and remained impaired after a 10-day taper, despite improved running performance. Locomotor changes may increase injury risk and should be considered within athlete monitoring programs independently of performance changes. 相似文献50.
Julia H. Vermylen Gordon J. Wood Elaine R. Cohen Jeffrey H. Barsuk William C. McGaghie Diane B. Wayne 《Journal of pain and symptom management》2019,57(3):682-687